Φορτώνει......
ALK inhibitors, resistance development, clinical trials
The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of the disease, based on oncogenic drivers, has led to the development of personalized medicine and the ability to deliver molecularly targeted...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Curr Oncol |
|---|---|
| Κύριοι συγγραφείς: | , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Multimed Inc.
2018
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6001759/ https://ncbi.nlm.nih.gov/pubmed/29910648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3760 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|